EMA Executive Director Recruitment: Leading the Future of Medicines Regulation

By João L. Carapinha

February 23, 2026

EMA Executive Director Recruitment

The EMA Executive Director Recruitment procedure has opened, a pivotal role overseeing operations like medicine authorizations, safety monitoring, and EU-wide public health responses. This vacancy, with reference COM/2026/20118, reports to the EMA Management Board, managing a 2025 budget of about EUR 600 million and 900 staff in a multilingual, multicultural setting in Amsterdam. As a Temporary Agent at grade AD 14, it offers a five-year renewable mandate under Regulation (EC) No 726/2004, seeking candidates with deep management expertise.

Core Leadership Duties

The Executive Director’s responsibilities include daily administration, staff leadership, strategic planning, budget management, and stakeholder relations that support EMA’s scientific and regulatory work. Selection emphasizes proven skills in managing large teams through changes like digital transformation, upholding multidisciplinary scientific evaluations, and advancing EMA’s global mission. Required expertise covers EU medicines laws, risk analysis (assessment, management, communication), and finances, plus strengths in healthcare sciences or pharmacology from public roles engaging pharma. This enables oversight of controls and partnerships with EU bodies, Member States, and international allies. Learn more in the official recruitment notice. Applications close 19 March 2026 via the EU portal

Reference url

Recent Posts

Joint Scientific Consultation EU
Joint Scientific Consultation EU Strategies for Medical Device Companies

By João L. Carapinha

June 19, 2026

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...
EU Joint Clinical Assessment
Insights on EU Joint Clinical Assessment for High-Risk Medical Devices

By João L. Carapinha

June 19, 2026

EU Joint Clinical Assessment is a distinct, harmonised process that operates separately from CE marking. It produces comparative clinical evidence on selected high-risk devices to support more consistent national reimbursement decisions across EU member states. Insights from the
USTR Germany Pharma Investigation
USTR Germany Pharma Investigation and its Impact on Global Drug Pricing

By João L. Carapinha

June 19, 2026

The USTR Germany Pharma Investigation has exposed how Germany’s pharmaceutical reimbursement policies force American patients to finance a disproportionately large share of worldwide drug research and development. By systematically suppressing prices below sustainable levels, these practices erod...